2019

    • March 10, 2021

    Nemaura Medical to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference

    Loughborough, England, March 10, 2021 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical...

    Read more
    March 4, 2021

    Nemaura Medical Appoints Industry Veteran Alistair Longmuir as Advisor on Global Product Manufacture Strategy

    Loughborough, England, March 04, 2021 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical...

    Read more
    March 3, 2021

    Nemaura Medical to Present at the H.C. Wainwright Global Life Sciences Conference

    Loughborough, England – March 3, 2021 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical...

    Read more
    February 5, 2021

    Nemaura Medical Appoints Thomas Mortensen as Head of E.U. Commercial Operations and Marketing

    Loughborough, England – February 4, 2021 (GlobeNewswire) – Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical...

    Read more
    February 1, 2021

    Nemaura Medical Appoints Jay L. Warner as Head of U.S. Commercial Operations

    Loughborough, England – February 1, 2021 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical...

    Read more
    December 17, 2020

    Nemaura Medical Launches BEAT®diabetes Program and Its Novel proBEAT™ Non-Invasive, Daily-Wear Adhesive Glucose Monitor

    Loughborough, England – December 17, 2020 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical...

    Read more
    September 3, 2020

    Nemaura Medical to Provide US proBEAT™ launch update at The LD 500 Virtual Conference

    Loughborough, England, September 03, 2020 – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused...

    Read more
    August 19, 2020

    Nemaura Medical issues Presentation Pertaining to the use of Continuous Glucose Monitoring in COVID-19 Patients

    Loughborough, England, August 19, 2020 – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused...

    Read more
    July 7, 2020

    Nemaura Medical Submits PMA Application for sugarBEAT® to U.S. FDA

    Company to Participate in RedChip Webinar on Tuesday, July 7, at 11 a.m. ET to Discuss Commercialization Progress Loughborough,...

    Read more
    June 30, 2020

    Nemaura Medical Reports Results and Provides Business Update for the Fiscal Year Ended March 31, 2020

    Loughborough, England, June 30, 2020 – Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a...

    Read more